PathAI logo


Immunohistochemistry (IHC) · Gastroenterology
C-MYC is a proto-oncogene at 8q24.1 produces short lived nuclear phosphoprotein that is overexpressed by t(8;14)(q24;q32.3), t(8;22);(q24;11) and t(2;8);(p11-12;q24), which translocate c-myc gene next to immunoglobulin genes in Burkitt’s lymphoma. C-MYC is amplified in 20-30% of breast cancer cases; associated with HER2 amplification and poor outcome. C-MYC expression in primary prostate tumor is biologically relevant and may be a predictor of future biochemical recurrence.